Skip to main content

View full-text article in PMC

. 2011 Nov 11;6:155. doi: 10.1186/1748-717X-6-155

Table 4.

Results based on univariate analysis

Parameters	p-value
Erythema (≥G1vs. G0) against skin mean dose	0.008
Erythema (≥G1vs. G0) against WB mean dose	0.008
Erythema (≥G1vs. G0) against V_{18 Gy}	0.009
Erythema (≥G1vs. G0) against PTV	0.010
Erythema (≥G1vs. G0) against PTV/WB	0.041

Telangectasia (≥G1vs. G0) against hormonal therapy	0.0178
Telangectasia (≥G1vs. G0) against V_18Gy>20%	0.032
Telangectasia (≥G1vs. G0) against V_21Gy>8%	0.0352
Telangectasia (≥G1vs. G0) against PTV > 97 cc	0.0406
Telangectasia (≥G1vs. G0) against previous acute erythema	0.0132

Late pain (≥G1vs. G0) against the upper quadrant	0.0446

Fibrosis/fat necrosis (≥G1vs. G0) against V_18Gy>20%	0.0258
Fibrosis/fat necrosis (≥G1vs. G0) against V_21Gy>66cc	0.00043
Fibrosis/fat necrosis (≥G1vs. G0) against WB mean dose>9Gy	0.0284
Fibrosis/fat necrosis (≥G1vs. G0) against PTV>97cc	0.0133
Fibrosis/fat necrosis (≥G2vs. G0-G1) against V_21Gy>66cc	0.0033

Cosmesis (good/excellent vs.poor/fair) and WB mean dose >9Gy	0.030
Cosmesis (good/excellent vs.poor/fair) and ≥G2 fibrosis	<0.0012
Cosmesis (good/excellent vs.poor/fair) and G3 fibrosis	0.0003